# Hydroxychloroquine in Combination With Encorafenib and Cetuximab or Panitumumab in the Treatment of Metastatic BRAF-mutated Colorectal Cancer Refractory

> **NCT05576896** · PHASE2 · RECRUITING · sponsor: **Northwestern University** · enrollment: 43 (estimated)

## Conditions studied

- Stage IV Colorectal Cancer Positive for BRAF V600E Mutation
- Colorectal Cancer
- Colorectal Cancer Stage IV

## Interventions

- **DRUG:** Hydroxychloroquine in Combination With Encorafenib and Cetuximab or Panitumumab

## Key facts

- **NCT ID:** NCT05576896
- **Lead sponsor:** Northwestern University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-10-10
- **Primary completion:** 2026-07-01
- **Final completion:** 2028-07-01
- **Target enrollment:** 43 (ESTIMATED)
- **Last updated:** 2025-10-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05576896

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05576896, "Hydroxychloroquine in Combination With Encorafenib and Cetuximab or Panitumumab in the Treatment of Metastatic BRAF-mutated Colorectal Cancer Refractory". Retrieved via AI Analytics 2026-07-16 from https://api.ai-analytics.org/clinical/NCT05576896. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*